Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-08-21

Clinical Trial Update: SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial update for SPD489 in adults with moderate to severe binge eating disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPD489

Snippet

Sponsor: Shire | Conditions: Binge Eating Disorder | Phase 3 | Status: COMPLETED | Results posted: 2014-08-21